NASDAQ:STIM Neuronetics - STIM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.92 +0.06 (+2.10%) (As of 03/29/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.86▼$3.0150-Day Range$2.81▼$6.4352-Week Range$1.98▼$6.95Volume87,275 shsAverage Volume264,988 shsMarket Capitalization$79.48 millionP/E RatioN/ADividend YieldN/APrice Target$9.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Neuronetics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside231.1% Upside$9.67 Price TargetShort InterestHealthy1.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 4 Articles This WeekInsider TradingSelling Shares$1.97 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.32) to ($1.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector317th out of 999 stocksSurgical & Medical Instruments Industry29th out of 103 stocks 3.5 Analyst's Opinion Consensus RatingNeuronetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.67, Neuronetics has a forecasted upside of 231.1% from its current price of $2.92.Amount of Analyst CoverageNeuronetics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.00% of the float of Neuronetics has been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuronetics has recently increased by 23.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for STIM. Previous Next 2.3 News and Social Media Coverage News SentimentNeuronetics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Neuronetics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for STIM on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat Follows5 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have sold 254.14% more of their company's stock than they have bought. Specifically, they have bought $556,473.00 in company stock and sold $1,970,668.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions62.90% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neuronetics are expected to grow in the coming year, from ($1.32) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Neuronetics (NASDAQ:STIM) StockNeuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.Read More Receive STIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter. Email Address STIM Stock News HeadlinesMarch 27, 2023 | marketwatch.comTMS (Transcranial Magnetic Stimulation) Coil Market Major Players, Anlysis and Forecast till 2031March 23, 2023 | americanbankingnews.comNeuronetics, Inc. (NASDAQ:STIM) Major Shareholder Acquires $151,008.80 in StockMarch 30, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 16, 2023 | finance.yahoo.comNeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PAMarch 15, 2023 | msn.comNeuronetics's Return On Capital Employed OverviewMarch 13, 2023 | marketwatch.comTMS (Transcranial Magnetic Stimulation) Coil Market Share, Segmentation and Forecast 2023-2028March 9, 2023 | finance.yahoo.comNeuronetics, Inc. (NASDAQ:STIM) Q4 2022 Earnings Call TranscriptMarch 3, 2023 | finance.yahoo.comNeuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered LivesMarch 30, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastFebruary 23, 2023 | finance.yahoo.comNeuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® PlatformFebruary 22, 2023 | finance.yahoo.comNeuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference CallFebruary 21, 2023 | finance.yahoo.comNeuronetics Sponsors the 5th International Brain Stimulation ConferenceFebruary 16, 2023 | finance.yahoo.comNeuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue OfficerFebruary 10, 2023 | finance.yahoo.comNeuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse PractitionersFebruary 5, 2023 | finance.yahoo.comNeuronetics, Inc. (STIM) Stock Historical Prices & Data - Yahoo FinanceJanuary 19, 2023 | finance.yahoo.comNeuronetics Inks Six-Year Exclusive Partnership With Greenbrook TMSJanuary 19, 2023 | finance.yahoo.comNeuronetics and Greenbrook TMS Announce Six Year Exclusive PartnershipJanuary 17, 2023 | finance.yahoo.comNeuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental HealthJanuary 10, 2023 | finance.yahoo.comNeuronetics Settles Litigation Against BrainsWayJanuary 9, 2023 | finance.yahoo.comNeuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial ResultsDecember 29, 2022 | finance.yahoo.comNeuronetics Announces Appointment of Joseph H. Capper to its Board of DirectorsDecember 22, 2022 | finance.yahoo.comOwning 50% shares,institutional owners seem interested in Neuronetics, Inc. (NASDAQ:STIM),December 6, 2022 | finance.yahoo.comNeuronetics (STIM) Is Up 12.75% in One Week: What You Should KnowDecember 5, 2022 | finance.yahoo.comNeuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care CategoryNovember 21, 2022 | finance.yahoo.comNeuronetics to Present at the Piper Sandler 34th Annual Healthcare ConferenceNovember 14, 2022 | finance.yahoo.comNeuronetics Announces NeuroStar® Advanced Therapy for Mental Health System InnovationsNovember 10, 2022 | finance.yahoo.comNeuronetics Third Quarter 2022 Earnings: Beats ExpectationsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive STIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter. Email Address STIM Company Calendar Last Earnings3/07/2023Today3/30/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STIM CUSIPN/A CIK1227636 Webwww.neurostar.com Phone(610) 640-4202Fax610-640-4206Employees175Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.67 High Stock Price Forecast$12.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+231.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,160,000.00 Net Margins-56.99% Pretax Margin-56.99% Return on Equity-56.07% Return on Assets-30.39% Debt Debt-to-Equity Ratio0.40 Current Ratio2.98 Quick Ratio2.71 Sales & Book Value Annual Sales$65.21 million Price / Sales1.22 Cash FlowN/A Price / Cash FlowN/A Book Value$2.10 per share Price / Book1.39Miscellaneous Outstanding Shares27,220,000Free Float25,806,000Market Cap$79.48 million OptionableNot Optionable Beta2.03 Key ExecutivesKeith J. SullivanPresident, Chief Executive Officer & DirectorStephen FurlongChief Financial Officer, Treasurer & Executive VPCory AndersonSVP- Research & Development & Clinical AffairsW. Andrew MacanSecretary, CCO, EVP & General CounselSara GrubbsChief Revenue Officer & Senior Vice PresidentKey CompetitorsNeovascNASDAQ:NVCNSensus HealthcareNASDAQ:SRTSPulse BiosciencesNASDAQ:PLSEBioventusNYSE:BVSLyra TherapeuticsNASDAQ:LYRAView All CompetitorsInsiders & InstitutionsCannell Capital LlcBought 52,072 shares on 3/16/2023Total: $151,008.80 ($2.90/share)Cannell Capital LlcBought 136,520 shares on 3/13/2023Total: $405,464.40 ($2.97/share)Cannell Capital LlcSold 7,746 sharesTotal: $36,483.66 ($4.71/share)Stephen FurlongSold 11,079 sharesTotal: $50,852.61 ($4.59/share)William Andrew MacanSold 12,692 sharesTotal: $58,256.28 ($4.59/share)View All Insider TransactionsView All Institutional Transactions STIM Stock - Frequently Asked Questions Should I buy or sell Neuronetics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STIM shares. View STIM analyst ratings or view top-rated stocks. What is Neuronetics' stock price forecast for 2023? 2 equities research analysts have issued 1-year target prices for Neuronetics' shares. Their STIM share price forecasts range from $7.00 to $12.00. On average, they expect the company's share price to reach $9.67 in the next twelve months. This suggests a possible upside of 231.1% from the stock's current price. View analysts price targets for STIM or view top-rated stocks among Wall Street analysts. How have STIM shares performed in 2023? Neuronetics' stock was trading at $6.87 at the start of the year. Since then, STIM stock has decreased by 57.5% and is now trading at $2.92. View the best growth stocks for 2023 here. Are investors shorting Neuronetics? Neuronetics saw a increase in short interest in March. As of March 15th, there was short interest totaling 256,700 shares, an increase of 23.6% from the February 28th total of 207,700 shares. Based on an average trading volume of 266,600 shares, the short-interest ratio is presently 1.0 days. Approximately 1.0% of the shares of the company are short sold. View Neuronetics' Short Interest. When is Neuronetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our STIM earnings forecast. How were Neuronetics' earnings last quarter? Neuronetics, Inc. (NASDAQ:STIM) issued its earnings results on Tuesday, March, 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.13. The business had revenue of $18.20 million for the quarter, compared to analyst estimates of $16.58 million. Neuronetics had a negative trailing twelve-month return on equity of 56.07% and a negative net margin of 56.99%. What ETFs hold Neuronetics' stock? ETFs with the largest weight of Neuronetics (NASDAQ:STIM) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC). What guidance has Neuronetics issued on next quarter's earnings? Neuronetics updated its first quarter 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $15.00 million-$16.00 million, compared to the consensus revenue estimate of $16.71 million. What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST). When did Neuronetics IPO? (STIM) raised $75 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. What is Neuronetics' stock symbol? Neuronetics trades on the NASDAQ under the ticker symbol "STIM." Who are Neuronetics' major shareholders? Neuronetics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Cannell Capital LLC (11.93%), Schroder Investment Management Group (3.22%), Silvercrest Asset Management Group LLC (2.90%), Divisadero Street Capital Management LP (2.33%), Morgan Stanley (1.61%) and First Eagle Investment Management LLC (1.35%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Gregory Harper, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan. View institutional ownership trends. How do I buy shares of Neuronetics? Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Neuronetics' stock price today? One share of STIM stock can currently be purchased for approximately $2.92. How much money does Neuronetics make? Neuronetics (NASDAQ:STIM) has a market capitalization of $79.48 million and generates $65.21 million in revenue each year. The company earns $-37,160,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. How many employees does Neuronetics have? The company employs 175 workers across the globe. How can I contact Neuronetics? Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The official website for the company is www.neurostar.com. The company can be reached via phone at (610) 640-4202, via email at ir@neuronetics.com, or via fax at 610-640-4206. This page (NASDAQ:STIM) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.